1 citations · 1 across the 4 of their papers we have counts for
4 papers
Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis
Sa Ren, Janharpreet Singh, Sandro Gsteiger +8
The use of amyloid-beta (A) clearance to support regulatory approvals of drugs in Alzheimer's disease (AD) remains controversial. We evaluate A as a potential trial-level sur…
Methods of multi-indication meta-analysis for health technology assessment: a simulation study
David Glynn, Pedro Saramago, Janharpreet Singh +4
A growing number of oncology treatments, such as bevacizumab, are used across multiple indications. However, in health technology assessment (HTA), their clinical and cost-effectiv…
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab
Sumayya Anwer, Janharpreet Singh, Sylwia Bujkiewicz +7
Background: Evidence maps have been used in healthcare to understand existing evidence and to support decision-making. In oncology they have been used to summarise evidence within…
Multi-indication evidence synthesis in oncology health technology assessment
Janharpreet Singh, Sumayya Anwer, Stephen Palmer +5
Background: Cancer drugs receive licensing extensions to include additional indications as trial evidence on treatment effectiveness accumulates. We investigate how sharing informa…